We are pleased to announce that Parkwalk has made an investment in Phoremost, a Cambridge University spinout, as part of a Series ‘B’ round of equity funding, alongside Amadeus Capital Partners and the University. Phoremost’s mission is to accelerate, diversify and rationalise drug discovery.

PhoreMost has developed a next-generation phenotypic screening platform called ‘SiteSeeker’ to identify the best new targets for future therapy, and crucially, how to drug them. This has the potential to significantly increase the diversity of novel therapeutics for cancer and other unmet diseases, where treatment options are currently severely limited.